Navigation Links
Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Date:9/23/2010

o TAXUS (7.4 percent for XIENCE V vs. 11.4 percent for TAXUS, p-value=0.0038).

In addition, XIENCE V demonstrated a 77 percent lower rate of stent thrombosis, defined as definite or probable according to ARC (0.9 percent for XIENCE V vs. 3.9 percent for TAXUS, p-value=<0.0001); a 60 percent lower rate of TVR (3.1 percent for XIENCE V vs. 7.7 percent for TAXUS, p-value=<0.0001); a 56 percent lower rate of TLR (2.6 percent XIENCE V vs. 5.9 percent TAXUS, p-value=0.0005); and a 49 percent lower rate of non-fatal MI (3.9 percent XIENCE V for vs. 7.6 percent for TAXUS, p-value=0.0009).

The stent thrombosis rate for XIENCE V between one and two years increased from 0.7 percent at one year to 0.9 percent at two years, while the TAXUS arm increased from 2.6 percent at one year to 3.9 percent at two years. At two years, 88.6 percent of XIENCE V patients and 84.8 percent of TAXUS patients had discontinued dual-antiplatelet therapy.

"The COMPARE results show that the gap in stent thrombosis rates between XIENCE V and TAXUS Liberte widened from 1.9 percent at one year to 3.0 percent at two years," said Charles A. Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "The COMPARE investigators have provided some of the first major insights into the comparative long-term differences in stent thrombosis rates between one and two years for different stent platforms."

"The two-year results presented today for the COMPARE trial and for the SPIRIT IV trial demonstrate impressive outcomes for XIENCE V compared to TAXUS Liberte and TAXUS Express, respectively," said Robert Hance, senior vice president, vascular, Abbott. "Both of these trials show the differences in the performance of these drug eluting stents and add to the ever-growing body of safety and efficacy data for XIENCE V – reinforcing why XIENCE V continues to be the market-leading drug eluting stent."

About The
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
2. New Data Reinforces Safety Profile of Abbotts Market-Leading XIENCE V(R) Drug Eluting Stent
3. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
4. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
5. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
6. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
7. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
8. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
9. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
10. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Lupin , Strides , ... Sub-licensees to Fourteen Companies     ... of its network of generic manufacturers to 14 companies now ... (ARVs). New companies Lupin and Strides Arcolab recently signed agreements ... MPP licensed from ViiV Healthcare two months after its approval ...
(Date:7/1/2015)... 2015 Research and ... the "Future Horizons and Growth Strategies in ... and Country Forecasts" report to their offering. ... the European Blood Banking Market 2015 is a ... current suppliers and potential market entrants identify and ...
(Date:7/1/2015)... DIEGO , July 1, 2015  AVACEN, Inc. announced ... second AVACEN patent covering the medical technology platform supporting its ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... apparatus and methods patent no. 9,066,781 - Methods And Apparatus ... manufactured by AVACEN and specific methods of use, referred to ...
Breaking Medicine Technology:The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3AVACEN Medical Patent Issued 2
... June 1 Reportlinker.com announces that a new market research report is available in its catalogue: , ... China Patient Monitoring Market Outlook to 2016 , , , ... , , China Patient Monitoring Market Outlook ... Summary , , , ...
... LIUZHOU CITY, Guangxi, China ... Group, Inc., (OTC Bulletin Board: CNBI), ("China BCT" or ... pharmaceutical products in Guangxi Province , China ... stores in Laibin,City, Xiangzhou County, further expanding the Company,s ...
Cached Medicine Technology:Reportlinker Adds China Patient Monitoring Market Outlook to 2016 2Reportlinker Adds China Patient Monitoring Market Outlook to 2016 3Reportlinker Adds China Patient Monitoring Market Outlook to 2016 4Reportlinker Adds China Patient Monitoring Market Outlook to 2016 5Reportlinker Adds China Patient Monitoring Market Outlook to 2016 6Reportlinker Adds China Patient Monitoring Market Outlook to 2016 7Reportlinker Adds China Patient Monitoring Market Outlook to 2016 8Reportlinker Adds China Patient Monitoring Market Outlook to 2016 9Reportlinker Adds China Patient Monitoring Market Outlook to 2016 10Reportlinker Adds China Patient Monitoring Market Outlook to 2016 11Reportlinker Adds China Patient Monitoring Market Outlook to 2016 12Reportlinker Adds China Patient Monitoring Market Outlook to 2016 13Reportlinker Adds China Patient Monitoring Market Outlook to 2016 14Reportlinker Adds China Patient Monitoring Market Outlook to 2016 15Reportlinker Adds China Patient Monitoring Market Outlook to 2016 16Reportlinker Adds China Patient Monitoring Market Outlook to 2016 17Reportlinker Adds China Patient Monitoring Market Outlook to 2016 18Reportlinker Adds China Patient Monitoring Market Outlook to 2016 19Reportlinker Adds China Patient Monitoring Market Outlook to 2016 20Reportlinker Adds China Patient Monitoring Market Outlook to 2016 21Reportlinker Adds China Patient Monitoring Market Outlook to 2016 22Reportlinker Adds China Patient Monitoring Market Outlook to 2016 23Reportlinker Adds China Patient Monitoring Market Outlook to 2016 24China BCT Acquires 11 Stores, Expanding Retail Pharmacy Network 2China BCT Acquires 11 Stores, Expanding Retail Pharmacy Network 3
(Date:7/2/2015)... ... July 02, 2015 , ... Evolved Ayurvedic Discoveries , ... an intention to partner with companies that share a similar mission of providing ... water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic herbs, are now available for ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Today, East Liverpool ... the Surgical Center at East Liverpool City Hospital (ELCH). Pam is currently the Chief ... of the director of surgery. Pam holds a master’s degree in health care administration ...
(Date:7/2/2015)... ... ... As part of the celebration of its 70th anniversary, the Thantakit International ... all around the world for their continuous patronage of the world-class services of their ... (indeed, Thantakit is one of the foremost places for dental tourism in Thailand) or ...
(Date:7/2/2015)... ... , ... Maddock Douglas is an internationally recognized firm that ... manage the increasing demand for innovation as a primary growth strategy, Maddock Douglas ... , Benkendorf is a seasoned management executive with more than 25 years of ...
(Date:7/1/2015)... ... July 01, 2015 , ... Dr. ... Georgia State University and a Georgia Research Alliance Eminent Scholar in Inflammation and ... therapeutics against middle-ear infections. , The grant from the National Institute on Deafness ...
Breaking Medicine News(10 mins):Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 3Health News:Thailand's Longest Established International Dental Center Celebrates Its 70th Anniversary with Promos Galore 2Health News:Business Builder Mark Benkendorf Joins Innovation Firm Maddock Douglas 2Health News:Institute for Biomedical Sciences Researcher Gets $1.6 Million to Develop Anti-Inflammatory Drug 2
... 15, 2007 The U.S. Pharmacopeia (USP) is ... dietary supplements for public notice and comment. ... Isoflavones monographs appeared in Pharmacopeial Forum (PF) 33(6), ... Turmeric, Powdered Turmeric, Powdered Turmeric Extract, Curcuminoids, Curcuminoids ...
... Nov. 15 Medical Services,International Inc. (Pink Sheets: MSITF) ... excellent independent test results obtained by regulatory,agencies related to ... the dual,VScan test kit that detects HIV and TB ... to be closely associated. It is very difficult to,get ...
... Launches Highly Accessible and ... Affordable Program ... YORK, Nov. 15 Chefs Diet(R), the leading meal,delivery service provider based ... My Solution -- a nationwide program that provides,chef-prepared, gourmet frozen meals for ...
... for Driver Safety Highlighted, WASHINGTON, Nov. 15 ... will hit the roads to spend time,with family and ... of the,11 million Americans with uncorrected vision problems. Depending ... could have,been eighteen years ago and some may never ...
... a study of more than 6,000 Los Angeles-area children ... Keck School of Medicine of the University of Southern California ... wall-eyed) and amblyopia (often referred to as lazy eye) were ... The study is currently available in the online edition of ...
... of men co-infected with herpes simplex virus type 2 (HSV-2) ... the levels of HIV in the blood and rectal secretions, ... This study is published in the November 15 issue ... , Most HIV-infected persons are also infected with HSV-2, ...
Cached Medicine News:Health News:USP announces 11 new proposed monographs for dietary supplements 2Health News:Medical Services Gets Significant Interest in Its Dual VScan Test Kit 2Health News:CHEFS DIET(R) Introduces My Solution 2Health News:Report Shows Millions May Be Driving with Uncorrected Visual Impairments 2Health News:Report Shows Millions May Be Driving with Uncorrected Visual Impairments 3Health News:USC study -- largest of its kind -- finds older children more likely to develop vision disorders 2Health News:Study shows suppressing herpes virus may reduce infectiousness of HIV 2
... of Alcon Acrylic, Chiron/Iolab LI-41 and Pharmacia & ... taller and thinner, maximizing the surface area around ... during loading and insertion, and makes it easy ... lens optic. The special direct-acting jaws release the ...
... 599 is the first full-featured combination automatic ... response on refraction results with visual acuities. ... at either 90 or 180 to accommodate ... HARK to the Humphrey Lens Analyzers for ...
Neomycin and Polymyxin B Sulfates and Hydrocortisone otic suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use....
Prednisolone Acetate ophthalmic suspension USP, 1% is an adrenocortical steroid product prepared as a sterile ophthalmic suspension....
Medicine Products: